Clinical trials: Endocrine System Disorder
Type 2 Diabetes
Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes
Increasing rates of type 2 diabetes among children and adolescents has considerable long-term implications not only for the affected individuals, but also for society and the health system as a whole.
- Trial name
- NCT01814787
- Testing
- CHICA Type 2 Diabetes Module
- Where
- United States
- Volunteers
- 1,369 people
- Sponsor
- Indiana University
Cardiovascular Diseases, Heart Diseases
Reducing Total Cardiovascular Risk in an Urban Community
PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus
- Trial name
- COACH (NCT00241904)
- Testing
- Lifestyle Changes, Antiplatelet Agents, Beta Blocker
- Where
- United States
- Volunteers
- 525 people
- Sponsor
- Johns Hopkins University
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT01059799)
- Testing
- insulin degludec, insulin glargine
- Where
- 53 sites in Hong Kong, Japan and 4 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.
- Trial name
- DURATION-NEO-1 (NCT01652716)
- Testing
- Exenatide once weekly suspension, Exenatide twice daily
- Where
- 58 sites in United States
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diabetes
User Performance Evaluation for DARIO™ BGMS
The study aims to evaluate the accuracy of the blood glucose level results obtained from fingertip using the Dario Blood Glucose Monitoring System (BGMS) compared to Yellow Springs Instrument (YSI) as well as to evaluate the…
- Trial name
- NCT02357043
- Testing
- Dario Blood Glucose Monitoring System, YSI
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- LabStyle Innovations Ltd.
Pleomorphic Adenoma of the Parotid, Warthin Tumor
Identification of Nerves Using Fluorescein Sodium
The purpose of this study is to see if there is benefit in using an IV contrast (sodium fluorescein) to identify nerves during head and neck surgery.
- Conditions
- Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck
- Trial name
- NCT06054178
- Testing
- Fluorescein Sodium
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Pancreatic Cancer
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100815
- Testing
- bevacizumab, capecitabine, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer
The purpose of this research study is to determine if it is possible to deliver high dose radiation in one week while also giving the drug capecitabine for the treatment of pancreatic cancer prior to surgery, to determine if this…
- Trial name
- NCT00889187
- Testing
- Neoadjuvant Short-Course Photon Radiation, Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
- Trial name
- NCT01474538
- Testing
- Insulin Lispro, Insulin Aspart
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Obesity
Metformin for Weight Loss in Schizophrenia
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
- Trial name
- NCT01177709
- Testing
- Metformin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Type I Diabetes Mellitus
Glutamine and Insulin Sensitivity in Type I Diabetes
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin…
- Trial name
- NCT01467063
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nemours Children's Clinic
Hypertension, Hyperlipidemia
Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk
The objective of this project is to develop and implement sophisticated point-of-care Electronic Health Record (EHR)-based clinical decision support that (a) identifies and (b) prioritizes all available evidence-based treatment…
- Conditions
- Hypertension, Hyperlipidemia, Diabetes, Smoking
- Trial name
- NCT01420016
- Testing
- Prioritized Clinical Decision Support
- Volunteers
- 7,914 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Diabetes Mellitus, Type 2
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications…
- Trial name
- ELEMENT 5 (NCT02302716)
- Testing
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Where
- 44 sites in United States, India and 5 more
- Volunteers
- 493 people
- Sponsor
- Eli Lilly and Company
Motor Activity, Health Behavior
Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes
This study plans to learn more about physical activity and physical function in sedentary older adults with type 2 diabetes.
- Conditions
- Motor Activity, Health Behavior, Diabetes Mellitus, Type 2
- Trial name
- NCT02473926
- Testing
- Physical Activity, Questionnaires
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Colorado, Denver
Diabetes Prevention in Women After GDM Who Are at High-risk
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Women with a history of gestational diabetes (GDM) are at substantially increased risk of type 2 diabetes mellitus (T2DM). Compared with the general population, these women are more likely to be overweight or obese.
- Trial name
- DAPA-GDM (NCT02338193)
- Testing
- DAPA/MET XR, DAPA, MET XR
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Woman's
Type 2 Diabetes Mellitus
Impact of Medicaid Health Home on Patients With Diabetes in New York City
Type 2 diabetes is common in the United States; about 1 in 10 people have the disease. Diabetes can cause devastating health events, such as hospitalizations, kidney failure, blindness, amputation, heart attack, stroke, painful…
- Trial name
- NCT02713321
- Where
- United States
- Volunteers
- 96,759 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Secondary Hyperparathyroidism, Chronic Kidney Disease
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (HPT) who…
- Trial name
- EVOLVE (NCT00345839)
- Testing
- Cinacalcet
- Volunteers
- 3,883 people
- Sponsor
- Amgen
Ovarian Cancer, Primary Peritoneal Serous Cancer
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
The purpose of this study is to evaluate how the participant's disease (ovarian, primary peritoneal serous, fallopian tube, or papillary serous endometrial cancer) responds to additional treatment with Avastin (bevacizumab).
- Conditions
- Ovarian Cancer, Primary Peritoneal Serous Cancer, Fallopian Tube Cancer
- Trial name
- NCT00866723
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Anemia, Secondary Hyperparathyroidism
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.
- Trial name
- NCT00431496
- Testing
- Cinacalcet
- Volunteers
- 71 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.